积极的Herizon-Gea-01三期结果支持Ziihera®(Zanidatamab-Hrii)作为首选的Her2靶向药物,Ziihera联合方案已成为一线Her2阳性局部晚期或转移性胃食管腺癌的新标准治疗。
积极的Herizon-Gea-01三期结果支持Ziihera®(Zanidatamab-Hrii)作为首选的Her2靶向药物,Ziihera联合方案已成为一线Her2阳性局部晚期或转移性胃食管腺癌的新标准治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.